CAMBRIDGE, England, June 22, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer's candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023.
WALTHAM, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of the Board, who resigned for personal reasons.
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components of an antibody amino acid sequence, to deeply understand the structure and function of antibody sequences. The article, titled “Deciphering the language of antibodies using self-supervised learning” has been published online in the journal Patterns. AntiBERTa is a 12-layer transformer model that provides a contextualized numeric representation of antibody sequences and learns biologically relevant information.
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, has been selected by NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1. Alchemab will use the NVIDIA DGX SuperPOD supercomputing cluster, powered by NVIDIA DGX A100 systems, to gain greater understanding and insights from its extensive neurology and oncology datasets.
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics - a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, has announced an extension of its collaboration with Medicines Discovery Catapult (MDC), a national facility enabling the UK’s community to accelerate innovative drug discovery.
BOSTON & CAMBRIDGE, U.K.--(BUSINESS WIRE)--Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of Young T. Kwon, PhD as Chief Financial and Operating Officer.
Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
Douglas Treco is a well-connected executive with a history of raising biotechs up to be acquired by bigger pharmaceutical companies.
Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer.